You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Input parameters used in the model

From: Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

         Variable Mean (SE) Sources
Clinical Variable (Transitional Probability)
RI-HSCT
Q1 state --> Death Vary Cohort, MOPH [10]
Q1 state --> BT-ICT 0.00003 Cohort
Q2 state --> Death Vary Cohort, MOPH [10]
Q2 state --> BT-ICT 0.0003 Cohort
Q3 state --> Death Age-specific Mortality MOPH [10]
Q3 state --> BT-ICT 0.00 Assumption
Q4 state --> Death Age-specific Mortality MOPH [10]
Q4 state --> BT-ICT 0.00 Assumption
Iron chelation state --> Death Age-specific Mortality MOPH [10]
Iron chelation state--> BT-ICT 0.00 Assumption
Post RI-HSCT --> Death Age-specific Mortality MOPH [10]
Post RI-HSCT--> BT-ICT 0.00 Assumption
BT-ICT (Severe Thalassemia patients)
BT-ICT Thal --> BT-ICT Thal with cardiac 0.0114 Borgna-Pignatti C et al.[11]
BT-ICT Thal --> Death Vary MOPH [10], Delea et al. [12], Gabutti & Piga [13]
BT-ICT Thal with cardiac --> Death Vary MOPH [10] and Chouliaras G [14]
Cost Variable (convert to US $) *,!
RI-HSCT   
Pre-BMT   
Direct Medical Cost 1,330 (438) Hospital Database#
Direct Non Medical Cost 75 (21) Survey
Indirect Cost 175 (42) Survey
Q1 state   
Direct Medical Cost 1,226 (169) Hospital Database#
Direct Non Medical Cost 458 (51) Survey
Indirect Cost 945 (105) Survey
Q2 state   
Direct Medical Cost 1,710 (381) Hospital Database#
Direct Non Medical Cost 335 (41) Survey
Indirect Cost 691 (85) Survey
Q3 state   
Direct Medical Cost 1,628 (538) Hospital Database#
Direct Non Medical Cost 259 (30) Survey
Indirect Cost 535 (62) Survey
Q4 state   
Direct Medical Cost 878 (282) Hospital Database#
Direct Non Medical Cost 253 (32) Survey
Indirect Cost 522 (66) Survey
Iron chelation state   
Direct Medical Cost 1,120 (238) Hospital Database#
Direct Non Medical Cost 539 (112) Survey
Indirect Cost 1,111 (230) Survey
Post RI-HSCT state   
Direct Non Medical Cost 1,548 (411) Hospital Database#
Direct non Medical Cost 299 (146 Survey
Indirect Cost 617 (301) Survey
BT-ICT (Severe Thalassemia patients)
Severe thalassemia patients without cardiac complications   
Direct Medical Cost 1,187 (137) Riewpariboon et al. [28]
Direct Non Medical Cost 1,240 (232) Leelahavaring et al. [29]
Indirect Cost 636 (221) Leelahavaring et al. [29]
Severe thalassemia patients with cardiac complications   
Direct Medical Cost 1,187 (137) Riewpariboon et al. [28]
Direct Non Medical Cost 1,240 (232) Leelahavaring et al. [29]
Indirect Cost 636 (221) Leelahavaring et al. [29]
Effectiveness Variable   
RI-HSCT   
Q1 state 0.59 (0.30) Survey
Q2 state 0.59 (0.30) Survey
Q3 state 0.59 (0.30) Survey
Q4 state 0.59 (0.30) Survey
Iron chelation state 0.88 (0.06) Survey
Post-RI-HSCT 0.90 (0.05) Survey
BT-ICT (Severe Thalassemia patients)   
Severe thalassemia patients without cardiac complications 0.61 (0.03) Osborne et al. [33]
Severe thalassemia patients with cardiac complications 0.46 (0.02) Osborne et al. [33]
  1. RI-HSCT: Reduced intensity hematopoietic stem cell, BT-ICT: Blood transfusion combined with subcutaneous iron chelating therapy, Pre-BMT: Pre-bone marrow transplantation.
  2. * ($US, year 2011 value).
  3. # Charges were converted to cost using a cost-to-charge ratio of 1.37 which was derived from Ramathibodi hospital for base-case analysis and 0.8-1.5 [27] for sensitivity analysis.
  4. ! Costs in Q1-Q4 is calculated for 3 month period, while costs beyond Q4 are on an annual basis.